Home Tirzepatide Side effects Thyroid C-cell tumour warning
Tirzepatide and Thyroid C-cell tumour warning
Boxed warning based on rodent data — the class carries a boxed warning regarding thyroid C-cell tumours observed in rodents; relevance to humans is not determined.
Boxed warning based on rodent data of participants in the tirzepatide trial program reported thyroid c-cell tumour warning — the class carries a boxed warning regarding thyroid C-cell tumours observed in rodents; relevance to humans is not determined.
In rodent studies, tirzepatide caused dose-dependent and duration-dependent thyroid C-cell tumours. Whether this translates to humans is unknown. The labeling contraindicates use in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. The warning applies for the duration of treatment.
Frequencies are approximate ranges from the published trial program and differ by dose, population and how events were collected. They are not a prediction for any individual.
| Reported frequency | Boxed warning based on rodent data |
|---|---|
| Typical onset | The warning applies for the duration of treatment. |
| Mechanism | In rodent studies, tirzepatide caused dose-dependent and duration-dependent thyroid C-cell tumours. Whether this translates to humans is unknown. The labeling contraindicates use in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. |
| Usually resolves | Variable — see below |
| Requires urgent review | Only if a red-flag symptom below is present |
Why tirzepatide causes thyroid c-cell tumour warning
In rodent studies, tirzepatide caused dose-dependent and duration-dependent thyroid C-cell tumours. Whether this translates to humans is unknown. The labeling contraindicates use in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.
When thyroid c-cell tumour warning starts and how long it lasts
The warning applies for the duration of treatment.
How to manage thyroid c-cell tumour warning on tirzepatide
- Disclose any personal or family history of medullary thyroid carcinoma or MEN 2 before starting
- Report a lump in the neck, hoarseness, difficulty swallowing or persistent shortness of breath
- Do not start if the contraindication applies to you
Thyroid C-cell tumour warning: when to contact a clinician
Seek medical advice promptly if any of the following occurs:
- A new neck lump or swelling
- Persistent hoarseness
- Difficulty swallowing or persistent breathlessness
Does thyroid c-cell tumour warning mean the tirzepatide dose is wrong?
Not necessarily. Adverse effects on tirzepatide cluster in the days after a dose increase and typically settle as the gut adapts. The usual response to a poorly tolerated step is to hold the current strength for another four weeks rather than to stop treatment or to climb faster. That decision belongs to your prescriber.
Frequently asked questions
Does tirzepatide cause thyroid cancer in people?
That has not been determined. The warning rests on rodent findings, and the contraindication is precautionary.
Do I need thyroid monitoring?
Routine calcitonin or ultrasound monitoring is not established as useful. Symptom reporting is what labeling directs.
People also ask about tirzepatide thyroid c-cell tumour warning
What is tirzepatide thyroid c-cell tumour warning?
Tirzepatide thyroid c-cell tumour warning is covered in full on this page, with the clinical detail drawn from the tirzepatide prescribing information and the published SURMOUNT and SURPASS trial program, and any price figures drawn from our tracked dataset and dated to their last verification.
Does tirzepatide thyroid c-cell tumour warning apply to compounded tirzepatide as well as Zepbound?
The molecule is the same, so the clinical content applies to both. What differs is regulatory status, dose metering and price: compounded preparations are not FDA-approved, arrive as a multi-dose vial you measure yourself, and cost a fraction of the brand routes.
How much does tirzepatide thyroid c-cell tumour warning cost per month in 2026?
Compounded tirzepatide runs from $133 per month at the entry dose across the 21 compounded programs we track. At a 10 mg maintenance dose the cheapest tracked route is Oak Longevity at $199 per month, or about $2,388 for a first year on the standard escalation. Brand Zepbound through manufacturer self-pay sits well above that and pharmacy retail well above again. Verified 2026-08-05.
Is tirzepatide thyroid c-cell tumour warning FDA-approved?
Brand tirzepatide (Zepbound and Mounjaro) is FDA-approved. Compounded tirzepatide is not: FDA does not approve compounded drugs and does not review them for safety, effectiveness or quality before they are marketed. The active molecule is the same; the regulatory review is not.
Sources
- US prescribing information for tirzepatide (Zepbound and Mounjaro), Eli Lilly and Company — dosing, storage, warnings and contraindications.
- SURMOUNT-1 — tirzepatide once weekly for the treatment of obesity, NCT04184622.
- SURPASS-2 — tirzepatide versus semaglutide 1 mg in type 2 diabetes, NCT03987919.
- Full source ledger — every primary source with a live link, what it supports, the date we read it, and the claims we deliberately do not source.